PL3666283T3 - Formulacje polipeptydu czynnika viii - Google Patents

Formulacje polipeptydu czynnika viii

Info

Publication number
PL3666283T3
PL3666283T3 PL19212900.5T PL19212900T PL3666283T3 PL 3666283 T3 PL3666283 T3 PL 3666283T3 PL 19212900 T PL19212900 T PL 19212900T PL 3666283 T3 PL3666283 T3 PL 3666283T3
Authority
PL
Poland
Prior art keywords
factor viii
viii polypeptide
polypeptide formulations
formulations
factor
Prior art date
Application number
PL19212900.5T
Other languages
English (en)
Inventor
Kevin Maloney
Ahmad ABDUL-FATTAH
Daniel GAGE
Original Assignee
Bioverativ Therapeutics Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50771579&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3666283(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bioverativ Therapeutics Inc. filed Critical Bioverativ Therapeutics Inc.
Publication of PL3666283T3 publication Critical patent/PL3666283T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PL19212900.5T 2013-03-15 2014-03-14 Formulacje polipeptydu czynnika viii PL3666283T3 (pl)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201361800293P 2013-03-15 2013-03-15
US201361817085P 2013-04-29 2013-04-29
US201361829884P 2013-05-31 2013-05-31
US201361839477P 2013-06-26 2013-06-26
US201361863860P 2013-08-08 2013-08-08
US201361876927P 2013-09-12 2013-09-12
US201361879955P 2013-09-19 2013-09-19
US201361897742P 2013-10-30 2013-10-30

Publications (1)

Publication Number Publication Date
PL3666283T3 true PL3666283T3 (pl) 2022-10-03

Family

ID=50771579

Family Applications (2)

Application Number Title Priority Date Filing Date
PL19212900.5T PL3666283T3 (pl) 2013-03-15 2014-03-14 Formulacje polipeptydu czynnika viii
PL14725816T PL2968477T3 (pl) 2013-03-15 2014-03-14 Formulacje polipeptydu czynnika viii

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL14725816T PL2968477T3 (pl) 2013-03-15 2014-03-14 Formulacje polipeptydu czynnika viii

Country Status (20)

Country Link
US (3) US9623088B2 (pl)
EP (3) EP4122487A1 (pl)
JP (5) JP6330026B2 (pl)
AU (4) AU2014228506A1 (pl)
CA (1) CA2899737A1 (pl)
CL (1) CL2015002720A1 (pl)
DK (1) DK2968477T3 (pl)
EA (2) EA030357B1 (pl)
ES (2) ES2776195T3 (pl)
HU (1) HUE047933T2 (pl)
LT (1) LT2968477T (pl)
PH (2) PH12015501801B1 (pl)
PL (2) PL3666283T3 (pl)
PT (2) PT3666283T (pl)
RS (1) RS60003B1 (pl)
SG (2) SG11201505924TA (pl)
SI (1) SI2968477T1 (pl)
TW (2) TWI629993B (pl)
UY (1) UY35462A (pl)
WO (1) WO2014144795A1 (pl)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2506868T3 (da) * 2009-12-06 2018-01-29 Bioverativ Therapeutics Inc Kimæriske og hybride faktor viii-fc-polypeptider og fremgangsmåder til anvendelse deraf
UY35463A (es) 2013-03-15 2014-10-31 Biogen Idec Inc Formulaciones de polipéptido fc-factor ix.
PL3666283T3 (pl) 2013-03-15 2022-10-03 Bioverativ Therapeutics Inc. Formulacje polipeptydu czynnika viii
CN106317226B (zh) 2016-08-19 2017-09-05 安源医药科技（上海）有限公司 用于构建融合蛋白的连接肽
CN106279437B (zh) * 2016-08-19 2017-10-31 安源医药科技（上海）有限公司 高糖基化人凝血因子viii融合蛋白及其制备方法与用途
WO2018102743A1 (en) 2016-12-02 2018-06-07 Bioverativ Therapeutics Inc. Methods of treating hemophilic arthropathy using chimeric clotting factors
US12257288B2 (en) 2016-12-02 2025-03-25 Bioverativ Therapeutics Inc. Methods of inducing immune tolerance to clotting factors
JP7039308B2 (ja) * 2017-02-08 2022-03-22 三洋化成工業株式会社 細胞培養用担体
MY203184A (en) 2017-08-09 2024-06-13 Bioverativ Therapeutics Inc Nucleic acid molecules and uses thereof
US10603275B2 (en) * 2017-11-07 2020-03-31 Rani Therapeutics, Llc Clotting factor preparations for delivery into tissue of the intestinal tract using a swallowable drug delivery device
SG11202010767SA (en) 2018-05-18 2020-11-27 Bioverativ Therapeutics Inc Methods of treating hemophilia a
MX2021001599A (es) 2018-08-09 2021-07-02 Bioverativ Therapeutics Inc Moleculas de acido nucleico y sus usos para la terapia genica no viral.
CA3115535A1 (en) * 2018-10-23 2020-04-30 The Children's Hospital Of Philadelphia Compositions and methods for modulating factor viii function
US20220088085A1 (en) * 2019-02-28 2022-03-24 Public University Corporation Yokohama City University Composition for treating blood coagulation and/or complement disorders
KR20220009389A (ko) 2019-04-17 2022-01-24 코디악 바이오사이언시즈, 인크. 엑소좀 및 aav 의 조성물
WO2020257462A1 (en) 2019-06-19 2020-12-24 Bioverativ Therapeutics Inc. Recombinant factor viii-fc for treating hemophilia and low bone mineral density
KR20230159285A (ko) * 2022-05-10 2023-11-21 주식회사 녹십자 혈장 단백질의 동결 건조를 위한 신규한 액상 제형물
WO2023219378A1 (ko) * 2022-05-10 2023-11-16 주식회사 녹십자 혈장 단백질에 대한 신규한 액상 제형물

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
DE3683980D1 (de) 1985-04-12 1992-04-02 Genetics Inst Neue prokoagulierungsproteine.
KR910006424B1 (ko) 1985-08-21 1991-08-24 인코텍스 비.브이 편성브리프(brief) 제조방법
WO1987004187A1 (en) 1986-01-03 1987-07-16 Genetics Institute, Inc. METHOD FOR PRODUCING FACTOR VIII:c-TYPE PROTEINS
US5595886A (en) 1986-01-27 1997-01-21 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
US5610278A (en) 1986-06-24 1997-03-11 Novo Nordisk A/S Process for producing a coagulation active complex of factor VIII fragments
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
CA1331157C (en) 1987-04-06 1994-08-02 Randal J. Kaufman Method for producing factor viii:c-type proteins
US6060447A (en) 1987-05-19 2000-05-09 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
IE69026B1 (en) 1987-06-12 1996-08-07 Immuno Ag Novel proteins with factor VIII activity process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
US6346513B1 (en) 1987-06-12 2002-02-12 Baxter Trading Gmbh Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
DE3720246A1 (de) 1987-06-19 1988-12-29 Behringwerke Ag Faktor viii:c-aehnliches molekuel mit koagulationsaktivitaet
FR2619314B1 (fr) 1987-08-11 1990-06-15 Transgene Sa Analogue du facteur viii, procede de preparation et composition pharmaceutique le contenant
US4994371A (en) 1987-08-28 1991-02-19 Davie Earl W DNA preparation of Christmas factor and use of DNA sequences
US5004803A (en) 1988-11-14 1991-04-02 Genetics Institute, Inc. Production of procoagulant proteins
CA2006596C (en) 1988-12-22 2000-09-05 Rika Ishikawa Chemically-modified g-csf
DK0461200T3 (da) 1989-02-21 1997-03-10 Univ Washington Modificerede former af reproduktionshormoner
SE465222C5 (sv) 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
CA2106079C (en) 1991-03-15 2000-04-25 Robert C. Thompson Pegylation of polypeptides
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US6376463B1 (en) 1992-04-07 2002-04-23 Emory University Modified factor VIII
US5859204A (en) 1992-04-07 1999-01-12 Emory University Modified factor VIII
US5364771A (en) 1992-04-07 1994-11-15 Emory University Hybrid human/porcine factor VIII
SK282483B6 (sk) * 1992-10-02 2002-02-05 Genetics Institute, Inc. Stabilná kompozícia koagulačného faktora VIII, spôsob jej prípravy a stabilizácie
US5563045A (en) 1992-11-13 1996-10-08 Genetics Institute, Inc. Chimeric procoagulant proteins
SE504074C2 (sv) 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
IL113010A0 (en) * 1994-03-31 1995-10-31 Pharmacia Ab Pharmaceutical formulation comprising factor VIII or factor ix with an activity of at least 200 IU/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
SE9503380D0 (sv) 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
US6458563B1 (en) 1996-06-26 2002-10-01 Emory University Modified factor VIII
US5763401A (en) 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
CA2225189C (en) 1997-03-06 2010-05-25 Queen's University At Kingston Canine factor viii gene, protein and methods of use
US6200560B1 (en) 1998-10-20 2001-03-13 Avigen, Inc. Adeno-associated virus vectors for expression of factor VIII by target cells
DK1820516T3 (da) 1999-02-22 2013-10-28 Univ Connecticut Nye albuminfrie faktor VIII-præparater
CN1406249B (zh) 2000-02-11 2010-06-16 默克专利股份有限公司 增加基于抗体的融合蛋白的循环半衰期
EP2277910A1 (en) 2001-12-21 2011-01-26 Human Genome Sciences, Inc. Albumin fusion proteins
GB0207092D0 (en) 2002-03-26 2002-05-08 Sod Conseils Rech Applic Stable pharmaceutical composition containing factor VIII
US7041635B2 (en) 2003-01-28 2006-05-09 In2Gen Co., Ltd. Factor VIII polypeptide
US7348004B2 (en) 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
HUE026384T2 (en) 2003-05-06 2016-06-28 Biogen Hemophilia Inc VII coagulation factor-FC chimeric proteins for the treatment of hemostasis disorder
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US7211559B2 (en) 2003-10-31 2007-05-01 University Of Maryland, Baltimore Factor VIII compositions and methods
KR20130026498A (ko) * 2003-12-19 2013-03-13 노보 노르디스크 헬스 케어 악티엔게젤샤프트 인자 ｖｉｉ 폴리펩티드의 안정화된 조성물
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
ES2633916T3 (es) 2004-11-12 2017-09-26 Bayer Healthcare Llc Modificación de FVIII dirigida al sitio
WO2007092772A2 (en) * 2006-02-03 2007-08-16 Medimmune, Inc. Protein formulations
US8048848B2 (en) 2006-02-03 2011-11-01 Prolor Biotech Ltd. Long-acting interferons and derivatives thereof and methods thereof
JP5448839B2 (ja) * 2006-12-22 2014-03-19 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー インビボで長い半減期を有する修飾された凝固因子
ES2362386T3 (es) 2007-06-21 2011-07-04 Technische Universität München Proteínas activas biológicas que tienen estabilidad aumentada in vivo y/o in vitro.
US8239182B2 (en) 2007-12-04 2012-08-07 Spansion Llc Data transmission system-on-chip memory model based validation
EP2242505A4 (en) 2008-01-08 2012-03-07 Biogenerix Ag GLYCOCONJUGATION OF POLYPEPTIDES USING OLIGOSACCHARYLTRANSFERASES
CN102482340B (zh) 2009-04-06 2015-05-13 诺沃—诺迪斯克有限公司 因子viii蛋白向血小板的靶向递送
DK2506868T3 (da) * 2009-12-06 2018-01-29 Bioverativ Therapeutics Inc Kimæriske og hybride faktor viii-fc-polypeptider og fremgangsmåder til anvendelse deraf
PL3513804T3 (pl) * 2011-07-08 2022-07-11 Bioverativ Therapeutics Inc. Chimeryczne i hybrydowe polipeptydy czynnika VIII i sposoby ich stosowania
EP2768853A1 (en) 2011-10-18 2014-08-27 CSL Limited Method for improving the stability of purified factor viii after reconstitution
WO2014026954A1 (en) * 2012-08-13 2014-02-20 Novo Nordisk A/S Liquid factor viii formulations
EP2914293A4 (en) * 2012-10-30 2016-04-20 Biogen Ma Inc METHOD OF USE OF FVIII POLYPEPTIDE
PL3666283T3 (pl) 2013-03-15 2022-10-03 Bioverativ Therapeutics Inc. Formulacje polipeptydu czynnika viii

Also Published As

Publication number Publication date
SG10201805207QA (en) 2018-07-30
JP7240457B2 (ja) 2023-03-15
AU2014228506A1 (en) 2015-08-13
PH12015501801A1 (en) 2015-11-09
PH12019502452A1 (en) 2021-02-08
US12403183B2 (en) 2025-09-02
JP2016516722A (ja) 2016-06-09
TWI690325B (zh) 2020-04-11
EP2968477A1 (en) 2016-01-20
JP2020186268A (ja) 2020-11-19
EA030357B1 (ru) 2018-07-31
AU2019202656A1 (en) 2019-05-09
AU2019202656B2 (en) 2021-09-02
JP2021181491A (ja) 2021-11-25
WO2014144795A1 (en) 2014-09-18
HK1220617A1 (en) 2017-05-12
ES2776195T3 (es) 2020-07-29
US20140308280A1 (en) 2014-10-16
DK2968477T3 (da) 2020-03-09
TWI629993B (zh) 2018-07-21
PT3666283T (pt) 2022-09-13
EP2968477B1 (en) 2019-12-04
TW201842930A (zh) 2018-12-16
JP6330026B2 (ja) 2018-05-23
CA2899737A1 (en) 2014-09-18
AU2025204069A1 (en) 2025-06-26
LT2968477T (lt) 2020-03-10
PT2968477T (pt) 2020-03-11
SG11201505924TA (en) 2015-09-29
UY35462A (es) 2014-10-31
EA201890671A1 (ru) 2019-01-31
CL2015002720A1 (es) 2016-11-04
AU2021277601B2 (en) 2025-03-06
JP7700164B2 (ja) 2025-06-30
PH12015501801B1 (en) 2019-11-20
US9623088B2 (en) 2017-04-18
JP2018123161A (ja) 2018-08-09
EP3666283A1 (en) 2020-06-17
PL2968477T3 (pl) 2020-06-15
TW201501722A (zh) 2015-01-16
SI2968477T1 (sl) 2020-04-30
US20170281734A1 (en) 2017-10-05
ES2926798T3 (es) 2022-10-28
AU2021277601A1 (en) 2021-12-23
US20210069300A1 (en) 2021-03-11
US10786554B2 (en) 2020-09-29
EA201591439A1 (ru) 2016-03-31
JP6934994B2 (ja) 2021-09-15
JP2023060146A (ja) 2023-04-27
HUE047933T2 (hu) 2020-05-28
RS60003B1 (sr) 2020-04-30
EP3666283B1 (en) 2022-06-08
EP4122487A1 (en) 2023-01-25

Similar Documents

Publication Publication Date Title
SG11201505924TA (en) Factor viii polypeptide formulations
GB201319791D0 (en) Formulations
GB201319792D0 (en) Formulations
SG11201505926VA (en) Factor ix polypeptide formulations
ZA201600729B (en) Peptides
IL245420A0 (en) New formulations
ZA201507684B (en) Recombinant factor viii formulations
ZA201504986B (en) Peptide
HUE050164T2 (hu) Új négy-CTL epitóp-kapcsolt peptid
ZA201504987B (en) Peptide
GB201309421D0 (en) Polypeptides
GB201315130D0 (en) Peptides
IL244956B (en) New peptide compositions
GB201316660D0 (en) Peptides
GB201300381D0 (en) Peptides
GB201305465D0 (en) Novel peptides
GB201317839D0 (en) Anti-Microbial peptides